诺和锐30与诺和灵30R对2型糖尿病血糖控制研究  

The study of biphsic insulin aspart 30 versus biphsic human insulin 30 in controlling glycemia of the type 2 diabetes

作　　者：郭念昆[1] 彭颜辉[1] 纪俊英[1] 

机构地区：[1]新疆医科大学第六附属医院内科,新疆乌鲁木齐830002

出　　处：《新疆医科大学学报》2007年第9期965-966,共2页Journal of Xinjiang Medical University

摘　　要：目的:比较诺和锐30与诺和灵30R控制2型糖尿病餐后血糖的差异。方法:采用随机临床对照试验的方法,将40例2型糖尿病患者分为诺和锐30组和诺和灵30R组,分别皮下注射诺和锐30胰岛素和诺和灵30R胰岛素,监测两组患者餐后血糖控制情况,并进行分析比较。结果:两组患者治疗前空腹血糖、餐后血糖值无明显差异,治疗后两组患者空腹血糖值无差异,餐后血糖值差异有统计学意义(P<0.05)。结论:诺和锐30控制早餐后血糖的作用优于诺和灵30R。Objective： To compare the difference of efficacy between biphsic insulin aspart 30 （30% fast-acting and 70% protamine-crystallised insulin aspart, BIAsp30） and biphsic human insulin 30（30% regular insulin and 70% NPH insulin, BHI 30） in the patients with type 2 diabetes. Methods： Forty cases of inadequate glycaemic control by oral antidiabetic drug were randomly divided into two groups using twice-daily insulin comparison of BIAsp30 and BHI 30. Efficacy was assessed after 20 days. Results： Significant improvements was observed in postprandial glycaemic control by using BIAsp30 （P 〈 0.05） and there was no differrence in fasting glycaemic control between two kinds of insulin. Conclusion： The rapid-acting insulin analog is superior to regular insulin in controlling postprandial glycaemic.

关 键 词：胰岛素 血糖控制 2型糖尿病 

分 类 号：R977.15[医药卫生—药品] R587.1[医药卫生—药学]